Answers are grounded in this paper and cite their sources.
The 11,12-cyclic carbazate of 3-keto-6-O-methylerythromycin A (4) was prepared. This compound shows in vitro antibacterial activity comparable to erythromycin A (1) against erythromycin-susceptible organisms and increased activity against some erythromycin-resistant organisms. Using 4 as a lead, a series of analogues was prepared by acylation or alkylation of the carbazate nitrogen. Several of the N-alkylated derivatives showed dramatically improved antibacterial activity against both susceptible and resistant organisms as compared to erythromycin A.
No takes yet. Share an insight, caveat, or question.
Griesgraber et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: